Research programme: anticancer therapeutics - AstraZeneca

Drug Profile

Research programme: anticancer therapeutics - AstraZeneca

Alternative Names: AZ-5576; AZD 5576; AZD 5597; AZD 5991

Latest Information Update: 19 Jul 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Small molecules
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Haematological malignancies

Most Recent Events

  • 06 Jul 2017 AstraZeneca plans a phase I trial of AZD 5991 for Haematological malignancies (Second-line therapy or greater, In adults, In the elderly) (IV) (NCT03218683)
  • 28 Mar 2017 Preclinical trials in Cancer in United Kingdom (unspecified route)
  • 16 Apr 2016 Preclinical trials in Haematological malignancies in USA (PO) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top